免疫原性
病毒学
免疫
抗体
免疫学
单核细胞增多症
医学
单克隆抗体
人性化鼠标
爱泼斯坦-巴尔病毒
病毒
免疫系统
作者
Harman Malhi,Leah J. Homad,Yu-Hsin Wan,Bibhav Poudel,Brooke Fiala,Andrew J. Borst,Jing Yang Wang,Carl Walkey,John F. Price,Abigail Wall,Suruchi Singh,Zoe Moodie,Lauren Carter,Simran Handa,Colin Correnti,Barry Stoddard,David Veesler,Marie Pancera,James M. Olson,Neil P. King,Andrew T. McGuire
标识
DOI:10.1016/j.xcrm.2022.100658
摘要
Epstein-Barr virus (EBV) is a cancer-associated pathogen responsible for 165,000 deaths annually. EBV is also the etiological agent of infectious mononucleosis and is linked to multiple sclerosis and rheumatoid arthritis. Thus, an EBV vaccine would have a significant global health impact. EBV is orally transmitted and has tropism for epithelial and B cells. Therefore, a vaccine would need to prevent infection of both in the oral cavity. Passive transfer of monoclonal antibodies against the gH/gL glycoprotein complex prevent experimental EBV infection in humanized mice and rhesus macaques, suggesting that gH/gL is an attractive vaccine candidate. Here, we evaluate the immunogenicity of several gH/gL nanoparticle vaccines. All display superior immunogenicity relative to monomeric gH/gL. A nanoparticle displaying 60 copies of gH/gL elicits antibodies that protect against lethal EBV challenge in humanized mice, whereas antibodies elicited by monomeric gH/gL do not. These data motivate further development of gH/gL nanoparticle vaccines for EBV.
科研通智能强力驱动
Strongly Powered by AbleSci AI